Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over Intergroup Trial

Next Previous
X
Search
Trial Profile

Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over Intergroup Trial

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
  • Indications Adenocarcinoma; Colon cancer; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms ADAGE; PRODIGE 34 ADAGE

    • Most Recent Events

    • 05 Jul 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Dec 2024.
    • 16 Aug 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Feb 2024.
    • 01 Apr 2023 Results(n=491 ) published in the Digestive and Liver Disease

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top